<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5730">
  <stage>Registered</stage>
  <submitdate>17/03/2015</submitdate>
  <approvaldate>17/03/2015</approvaldate>
  <nctid>NCT02400307</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics of GS-9883 in Adults With Normal and Impaired Renal Function</studytitle>
    <scientifictitle>A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-000898-12</secondaryid>
    <secondaryid>GS-US-141-1479</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-9883

Experimental: Severe Renal Impairment - Participants with severe renal impairment and matched healthy controls will receive a single dose of GS-9883.

Experimental: Moderate Renal Impairment - Participants with moderate renal impairment and matched healthy controls will receive a single dose of GS-9883.

Experimental: Mild Renal Impairment - Participants with mild renal impairment and matched healthy controls will receive a single dose of GS-9883.


Treatment: drugs: GS-9883
GS-9883 75 mg tablet administered orally

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve extrapolated to infinite time (AUCinf) for GS-9883</outcome>
      <timepoint>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve from zero to the last quantifiable concentration (AUC_0-last) for GS-9883</outcome>
      <timepoint>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) of GS-9883</outcome>
      <timepoint>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of treatment-emergent adverse events (AEs) and treatment-emergent laboratory abnormalities</outcome>
      <timepoint>Up to 31 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  All Individuals:

               -  Must have a calculated BMI from 18 to 40 kg/m^2, inclusive, at screening

          -  Individuals with impaired renal function

               -  Chronic stable renal impairment without recent clinical change

                    -  Mild: Creatinine clearance (CrCl) = 60 - 89 mL/min

                    -  Moderate: CrCl = 30 - 59 mL/min

                    -  Severe: CrCl = 15 - 29 mL/min

          -  Healthy individuals

               -  CrCl = 90 mL/min</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  All Individuals:

               -  Pregnant or lactating females

               -  HIV positive or chronic hepatitis B infected

          -  Individuals with impaired renal function

               -  Chronic liver disease

               -  Dialysis or anticipated use of dialysis

               -  Renal transplant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the pharmacokinetic (PK) profile, safety, and tolerability of oral
      GS-9883 in adults with impaired renal function relative to matched, healthy controls with
      normal renal function. Each participant in the renal impairment groups will be matched for
      age (± 10 years), gender, and body mass index [BMI (± 20%, 18 = BMI = 40 kg/m^2)] with a
      participant in the control group.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02400307</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Devi SenGupta, MD</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>